ICCC ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 The Zacks Analyst Blog Highlights Alphabet, Mastercard, AbbVie, Perma-Pipe and ImmuCell GOOGL, MA and ABBV headline today's research, with AI-led growth, electronic payments and strong drug portfolios shaping their outlooks. | ||
Top Research Reports for Alphabet, Mastercard & AbbVie Alphabet's AI-led cycle is strengthening Search, Cloud and subscriptions, while rising investment and regulatory risks create uncertainty around returns. | ||
 ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2 ICCC's Q2 sales rise 11.5% y/y, but margins contract. A $2-million legal settlement boosts profit as the company plans a capacity expansion. | ||
 ImmuCell (ICCC) Q2 2026 Earnings Call Transcript Product sales hit $7.2 million as market share climbed to 19% amid capacity expansion plans. | ||
ImmuCell Corp (ICCC) (Q2 2026) Earnings Call Highlights: Record Net Income and Market Share ... ImmuCell Corp (ICCC) reports 11.5% sales growth and a 19% U.S. market share, while investing $8 million to triple manufacturing capacity. | ||
 ImmuCell Q2 Earnings Call Highlights ImmuCell (NASDAQ:ICCC) reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027. Product sales rose 11.5% year ove | ||
 ImmuCell Corporation Q2 2026 Earnings Call Summary Moby summary of ImmuCell Corporation's Q2 2026 earnings call | ||